| Literature DB >> 30104205 |
Pei-Hui Wang1, Zi-Wei Ye2, Jian-Jun Deng1, Kam-Leung Siu1, Wei-Wei Gao1, Vidyanath Chaudhary1, Yun Cheng1, Sin-Yee Fung1, Kit-San Yuen1, Ting-Hin Ho1, Ching-Ping Chan1, Yan Zhang3, Kin-Hang Kok2, Wanling Yang3, Chi-Ping Chan1, Dong-Yan Jin4.
Abstract
Mouse p202 is a disease locus for lupus and a dominant-negative inhibitor of AIM2 inflammasome activation. A human homolog of p202 has not been identified so far. Here, we report a novel transcript isoform of human IFI16-designated IFI16-β, which has a domain architecture similar to that of mouse p202. Like p202, IFI16-β contains two HIN domains, but lacks the pyrin domain. IFI16-β is ubiquitously expressed in various human tissues and cells. Its mRNA levels are also elevated in leukocytes of patients with lupus, virus-infected cells, and cells treated with interferon-β or phorbol ester. IFI16-β co-localizes with AIM2 in the cytoplasm, whereas IFI16-α is predominantly found in the nucleus. IFI16-β interacts with AIM2 to impede the formation of a functional AIM2-ASC complex. In addition, IFI16-β sequesters cytoplasmic dsDNA and renders it unavailable for AIM2 sensing. Enforced expression of IFI16-β inhibits the activation of AIM2 inflammasome, whereas knockdown of IFI16-β augments interleukin-1β secretion triggered by dsDNA but not dsRNA Thus, cytoplasm-localized IFI16-β is functionally equivalent to mouse p202 that exerts an inhibitory effect on AIM2 inflammasome.Entities:
Keywords: AIM2; IFI16; inflammasome; transcript isoform
Mesh:
Substances:
Year: 2018 PMID: 30104205 PMCID: PMC6172465 DOI: 10.15252/embr.201845737
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807